Pharmacogene Variants Associated with Liver Transplant in a Twelve-Year Clinical Follow-Up

Pharmacogene Variants Associated with Liver Transplant in a Twelve-Year Clinical Follow-Up

Some gene polymorphisms have been previously associated individually with tacrolimus efficacy and toxicity, but no long-term study to determine the role of pharmacogene variants in the clinical evolution of liver-transplanted patients has been addressed so far. In the present work, we analyzed the r...

Full description

Bibliographic Details
Main Authors:	Luis Sendra, Gladys G. Olivera, Rafael López-Andújar, Cristina Serrano, Luis E. Rojas, Eva María Montalvá, María José Herrero, Salvador F. Aliño
Format:	Article
Language:	English
Published:	MDPI AG 2022-02-01
Series:	Pharmaceutics
Subjects:	pharmacogenetics immunosuppressant ABC CYP SLCO
Online Access:	https://www.mdpi.com/1999-4923/14/2/354

Similar Items

Comprehensive characterization of pharmacogenes in a Taiwanese Han population
by: Hsing-Fang Lu, et al.
Published: (2022-08-01)

Influence of <it>SLCO1B1 </it>and <it>CYP2C8 </it>gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers
by: Aquilante Christina L, et al.
Published: (2008-09-01)

Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites
by: Yuanhuang Chen, et al.
Published: (2021-06-01)

Allelic diversity of the pharmacogene CYP2D6 in New Zealand Māori and Pacific peoples
by: Leonie M. Hitchman, et al.
Published: (2022-10-01)

Genetic Variation among Pharmacogenes in the Sardinian Population
by: Maria Laura Idda, et al.
Published: (2022-09-01)

Use of Pharmacogenetic Drugs by the Dutch Population
by: Mohammad A. Alshabeeb, et al.
Published: (2019-07-01)

SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability
by: Pablo Zubiaur, et al.
Published: (2021-03-01)

Large-scale next generation sequencing based analysis of SLCO1B1 pharmacogenetics variants in the Saudi population
by: Ewa Goljan, et al.
Published: (2024-03-01)

A Comprehensive Analysis of 21 Actionable Pharmacogenes in the Spanish Population: From Genetic Characterisation to Clinical Impact
by: Rocio Nunez-Torres, et al.
Published: (2023-04-01)

APPLIED ASPECTS OF SLCO1B1 PHARMACOGENETIC TESTING FOR PREDICTING OF STATIN-INDUCED MYOPATHY AND PERSONALIZATION OF STATINS THERAPY
by: D. A. Sychev, et al.
Published: (2015-09-01)

Influence of pharmacogenetics on the diversity of response to statins associated with adverse drug reactions
by: Sainz de Medrano Sainz Jaime I., et al.
Published: (2023-10-01)

The frequency of SLCO1B1*5 polymorphism genotypes among Russian and Sakha (Yakutia) patients with hypercholesterolemia
by: Sychev DA, et al.
Published: (2016-05-01)

Genetic Polymorphisms Affecting Tacrolimus Metabolism and the Relationship to Post-Transplant Outcomes in Kidney Transplant Recipients
by: Cheng F, et al.
Published: (2021-11-01)

Impact of SLCO1B1*5 on Flucloxacillin and Co-Amoxiclav–Related Liver Injury
by: Mohammad Alshabeeb, et al.
Published: (2022-06-01)

Genetic polymorphisms of CYP2B6*6, CYP2C8*3 and CYP2D6*4 in vivax malaria patients from Brazilian Amazon
by: José Pereira de Moura Neto, et al.
Published: (2023-11-01)

Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma
by: Maud Maillard, et al.
Published: (2020-12-01)

<i>MTHFR</i> and <i>VDR</i> Polymorphisms Improve the Prognostic Value of <i>MYCN</i> Status on Overall Survival in Neuroblastoma Patients
by: Gladys G. Olivera, et al.
Published: (2020-04-01)

SLCO1B1 and CYP3A4 allelic variants associated with pharmacokinetic interactions and adverse reactions induced by simvastatin and atorvastatin used in Peru: Clinical implications
by: Angel T. Alvarado, et al.
Published: (2023-11-01)

Identification of Transporter Polymorphisms Influencing Metformin Pharmacokinetics in Healthy Volunteers
by: Miriam Saiz-Rodríguez, et al.
Published: (2023-03-01)

Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the Chilean population: comparison with Caucasian and Asian populations
by: Angela Margarita Roco, et al.
Published: (2012-11-01)

Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions? Observations and introspection of the bioanalysis
by: Thakkar D, et al.
Published: (2017-04-01)

Failure of Achieving Tacrolimus Target Blood Concentration Might Be Avoided by a Wide Genotyping of Transplanted Patients: Evidence from a Retrospective Study
by: Giovanni Pallio, et al.
Published: (2020-06-01)

Evaluation of the effect of the carrier of polymorphic variants of the SLCO1B1 gene on efficacy and safety in patients during treatment with statins
by: N. A. Rumyantsev, et al.
Published: (2018-02-01)

The Clinical Impact of the C0/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients
by: Teun van Gelder, et al.
Published: (2020-07-01)

CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings
by: Amber L. Beitelshees, et al.
Published: (2022-02-01)

CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic
by: Seyed abbas Mirabbasi, et al.
Published: (2017-07-01)

Practice of CYP450 genotyping and phenotyping in children in a real-life setting
by: Frédérique Rodieux, et al.
Published: (2023-02-01)

CYP2C19*2 Polymorphism Is Associated with Impaired Oral Clearance of Gliclazide in Healthy Chinese
by: Chow E, et al.
Published: (2020-01-01)

Whole genome amplification of DNA for genotyping pharmacogenetics candidate genes.
by: Santosh ePhilips, et al.
Published: (2012-03-01)

Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy
by: N A Rumyantsev, et al.
Published: (2017-01-01)

SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals
by: Yalena Prado, et al.
Published: (2015-08-01)

Pharmacogenetic Approaches to Enhancing Efficacy and Safety of Statins as Illustrated by the Example of Atorvastatin
by: R. Ye. Kazakov, et al.
Published: (2020-03-01)

Rates of Divergent Pharmacogenes in a Psychiatric Cohort of Inpatients with Depression—Arguments for Preemptive Testing
by: Sibylle Christine Roll, et al.
Published: (2022-10-01)

Economic Evaluation of Multiple-Pharmacogenes Testing for the Prevention of Adverse Drug Reactions in People Living with HIV
by: Turongkaravee S, et al.
Published: (2022-07-01)

Life-Threatening Docetaxel Toxicity in a Patient With Reduced-Function CYP3A Variants: A Case Report
by: Nicholas R. Powell, et al.
Published: (2022-01-01)

Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene
by: Trdan Lušin Tina, et al.
Published: (2012-04-01)

Personalized Medicine in Infant Population with Cancer: Pharmacogenetic Pilot Study of Polymorphisms Related to Toxicity and Response to Chemotherapy
by: Andrea Urtasun, et al.
Published: (2023-02-01)

Frecuencia de la variante alélica CYP2D6*6 en una muestra de la población cubana
by: Hilda Roblejo Balbuena, et al.

Association between CYP2C19 and CYP2B6 phenotypes and the pharmacokinetics and safety of diazepam
by: Pablo Zubiaur, et al.
Published: (2022-11-01)

SLCO1B1 and ABCG2 Gene Polymorphisms in a Thai Population
by: Rattanacheeworn P, et al.
Published: (2020-10-01)